Screener
Zymeworks ZYME Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -419%-352pp | -140.4%-6.6pp | -87.3%+92.3pp | -52.5%+170pp | -67.3%+152pp | |
| Net margin | -404%-344pp | -126.3%-4.6pp | -76.6%+84.2pp | -47.2%+136pp | -60%+119pp | |
| Returns | ||||||
| Return on equity | -72.3%-52.4pp | -42%-12.2pp | -26.7%+3.8pp | -18.5%+10.3pp | -19.9%+6.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.2× | 0.2×0.0× | 0.3×+0.1× | 0.3×+0.2× | 0.3×+0.2× | |
| Liquidity | ||||||
| Current ratio | 6.3×-1.4× | 10.8×+6.1× | 5.9×+2.5× | 6.9×+2.8× | 7.7×+0.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $1.10-74.5% | $2.19-49.3% | $3.56-20.3% | $4.22-12.3% | $4.32-18.7% | |
| Valuation | ||||||
| Market capitalization | $1.7B+83.2% | $1.86B+125% | $1.99B+96.9% | $1.29B+45.8% | $959.51M+82.8% | |
| Price / sales | 45.8×+38.3× | 22.9×+14.0× | 18.7×+5.5× | 9.6×-4.6× | 7.8×-0.6× | |
| Price / book | 21.2×+18.4× | 11.4×+8.8× | 7.4×+4.4× | 4×+1.6× | 2.9×+1.6× |
FAQ
- Where do Zymeworks's ratios come from?
- Every ratio is computed from Zymeworks's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
